Myriad has acquired Sividon on 31 May for EUR 35 million upfront with the potential for EUR 15 million in additional performance-based milestones. Sividon Diagnostics was spun out of Siemens Healthcare Diagnostics in 2010 as part of a management buyout and subsequently financed by venture capital funds and state-owned development bank KfW. Sividon's core product; the EndoPredict® test; will be the foundational product of Myriad's newly initiated kit-based strategy and allow Myriad to leverage its global oncology distribution to bring this important test to patients worldwide.